OXFORD BIOMEDICA PLC (OXB.L)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in GBP.

Revenue Annual

0 60M 120M 180M 2021: 142.8M 2022: 140M 2023: 89.5M 2024: 128.8M 2025: 168.7M 2021 2022 2023 2024 2025

Gross Profit Annual

0 30M 60M 90M 2021: 82.6M 2022: 69.2M 2023: 39.7M 2024: 53M 2025: 66M 2021 2022 2023 2024 2025

Operating Income Annual

-210M -140M -70M 0 70M 140M 210M 2021: 20.8M 2022: -30.2M 2023: -184.2M 2024: -39.4M 2025: -22.5M 2021 2022 2023 2024 2025

Net Income Annual

-210M -140M -70M 0 70M 140M 210M 2021: 19M 2022: -45.2M 2023: -184.2M 2024: -48.6M 2025: -30.6M 2021 2022 2023 2024 2025

Cost of Revenue Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M 2021: 25.5M 2022: -12.6M 2023: -28.5M 2024: -50.7M 2025: 507K 2021 2022 2023 2024 2025

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M 2021: 16M 2022: -28.9M 2023: -38.3M 2024: -58.2M 2025: -4.3M 2021 2022 2023 2024 2025

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

EPS TTM

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.